S'abonner

Safety and efficacy of a three-dose regimen of Plasmodium falciparum sporozoite vaccine in adults during an intense malaria transmission season in Mali: a randomised, controlled phase 1 trial - 24/02/22

Doi : 10.1016/S1473-3099(21)00332-7 
Mahamadou S Sissoko, MD a, *, Sara A Healy, MD b, *, Abdoulaye Katile, MD a, Irfan Zaidi, PhD b, Zonghui Hu, PhD c, Bourama Kamate, MD a, Yacouba Samake, MD a, Kourane Sissoko, MD a, Agnes Mwakingwe-Omari, MD b, e, Jacquelyn Lane, PA-C b, Alemush Imeru, BS b, Rathy Mohan, PhD b, Ismaila Thera, MSc a, Cheick Oumar Guindo, MD a, Amagana Dolo, PharmD a, Karamoko Niare, PhD a, Fanta Koïta, PharmD a, Amadou Niangaly, PharmD a, Kelly M Rausch a, Amatigue Zeguime, PharmD a, Merepen A Guindo, PharmD a, Aissatou Bah, BS b, d, Yonas Abebe, MS f, Eric R James, PhD f, Anita Manoj, MS f, Tooba Murshedkar, MS f, Natasha KC, BS f, g, B Kim Lee Sim, PhD f, g, Peter F Billingsley, PhD f, Thomas L Richie, MD f, Stephen L Hoffman, ProfMD f, , Ogobara Doumbo, ProfMD a, , Patrick E Duffy, MD b, ,
a Malaria Research and Training Center, Mali-NIAID ICER, University of Science, Techniques and Technologies of Bamako, Mali 
b Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA 
c Biostatistical Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA 
d Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA 
e Center for Vaccine Research, GlaxoSmithKline, Rockville, MD, USA 
f Sanaria, Rockville, MD, USA 
g Protein Potential, Rockville, MD, USA 

* Correspondence to: Dr Patrick E Duffy, Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20814, USA Laboratory of Malaria Immunology and Vaccinology National Institute of Allergy and Infectious Diseases National Institutes of Health Bethesda MD 20814 USA

Summary

Background

WHO recently approved a partially effective vaccine that reduces clinical malaria in children, but increased vaccine activity is required to pursue malaria elimination. A phase 1 clinical trial was done in Mali, west Africa, to assess the safety, immunogenicity, and protective efficacy of a three-dose regimen of Plasmodium falciparum sporozoite (PfSPZ) Vaccine (a metabolically active, non-replicating, whole malaria sporozoite vaccine) against homologous controlled human malaria infection (CHMI) and natural P falciparum infection.

Methods

We recruited healthy non-pregnant adults aged 18–50 years in Donéguébougou, Mali, and surrounding villages (Banambani, Toubana, Torodo, Sirababougou, Zorokoro) for an open-label, dose-escalation pilot study and, thereafter, a randomised, double-blind, placebo-controlled main trial. Pilot study participants were enrolled on an as-available basis to one group of CHMI infectivity controls and three staggered vaccine groups receiving: one dose of 4·5 × 105, one dose of 9 × 105, or three doses of 1·8 × 106 PfSPZ via direct venous inoculation at approximately 8 week intervals, followed by homologous CHMI 5 weeks later with infectious PfSPZ by direct venous inoculation (PfSPZ Challenge). Main cohort participants were stratified by village and randomly assigned (1:1) to receive three doses of 1·8 × 106 PfSPZ or normal saline at 1, 13, and 19 week intervals using permuted block design by the study statistician. The primary outcome was safety and tolerability of at least one vaccine dose; the secondary outcome was vaccine efficacy against homologous PfSPZ CHMI (pilot study) or against naturally transmitted P falciparum infection (main study) measured by thick blood smear. Combined artesunate and amodiaquine was administered to eliminate pre-existing parasitaemia. Outcomes were analysed by modified intention to treat (mITT; including all participants who received at least one dose of investigational product; safety and vaccine efficacy) and per protocol (vaccine efficacy). This trial is registered with ClinicalTrials.gov, number NCT02627456.

Findings

Between Dec 20, 2015, and April 30, 2016, we enrolled 56 participants into the pilot study (five received the 4·5 × 105 dose, five received 9 × 105, 30 received 1·8 × 106, 15 were CHMI controls, and one withdrew before vaccination) and 120 participants into the main study cohort with 60 participants assigned PfSPZ Vaccine and 60 placebo in the main study. Adverse events and laboratory abnormalities post-vaccination in all dosing groups were few, mainly mild, and did not differ significantly between vaccine groups (all p>0·05). Unexpected severe transaminitis occured in four participants: one participant in pilot phase that received 1·8 × 106 PfSPZ Vaccine, one participant in main phase that received 1·8 × 106 PfSPZ Vaccine, and two participants in the main phase placebo group. During PfSPZ CHMI, approximately 5 weeks after the third dose of 1·8 × 106 PfSPZ, none of 29 vaccinees and one of 15 controls became positive on thick blood smear; subsequent post-hoc PCR analysis for submicroscopic blood stage infections detected P falciparum parasites in none of the 29 vaccine recipients and eight of 15 controls during CHMI. In the main trial, 32 (58%) of 55 vaccine recipients and 42 (78%) of 54 controls became positive on thick blood smear during 24-week surveillance after vaccination. Vaccine efficacy (1–hazard ratio) was 0·51 per protocol (95% CI 0·20–0·70; log-rank p=0·0042) and 0·39 by mITT (0·04–0·62; p=0·033); vaccine efficacy (1–risk ratio) was 0·24 per-protocol (0·02–0·41; p=0·031) and 0·22 mITT (0·01–0·39; p=0·041).

Interpretation

A three-dose regimen of PfSPZ Vaccine was safe, well tolerated, and conferred 51% vaccine efficacy against intense natural P falciparum transmission, similar to 52% vaccine efficacy reported for a five-dose regimen in a previous trial.

Funding

US National Institute of Allergy and Infectious Diseases, National Institutes of Health, Sanaria.

Translation

For the French translation of the abstract see Supplementary Materials section.

Le texte complet de cet article est disponible en PDF.

Plan


© 2022  Elsevier Ltd. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 22 - N° 3

P. 377-389 - mars 2022 Retour au numéro
Article précédent Article précédent
  • Supervised versus unsupervised primaquine radical cure for the treatment of falciparum and vivax malaria in Papua, Indonesia: a cluster-randomised, controlled, open-label superiority trial
  • Jeanne Rini Poespoprodjo, Faustina Helena Burdam, Freis Candrawati, Benedikt Ley, Niamh Meagher, Enny Kenangalem, Ratni Indrawanti, Leily Trianty, Kamala Thriemer, David J Price, Julie A Simpson, Ric N Price
| Article suivant Article suivant
  • The clinical and microbiological efficacy of temocillin versus cefotaxime in adults with febrile urinary tract infection, and its effects on the intestinal microbiota: a randomised multicentre clinical trial in Sweden
  • Charlotta Edlund, Anders Ternhag, Gunilla Skoog Ståhlgren, Petra Edquist, Åse Östholm Balkhed, Simon Athlin, Emeli Månsson, Maria Tempé, Jakob Bergström, Christian G Giske, Håkan Hanberger, Temocillin Study Group, Charlotta Edlund, Anders Ternhag, Gunilla Skoog Ståhlgren, Petra Edquist, Åse Östholm Balkhed, Simon Athlin, Emeli Månsson, Maria Tempé, Jakob Bergström, Christian G Giske, Daniel Holmström, Anna-Karin Lindgren, Gisela Otto, Maria Furberg, Johan Fält, Elin Hedman, Håkan Hanberger

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.